- Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
- Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
- Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
- Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
- Allakos Announces a Restructuring to Focus on Development of AK006
- Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
- Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
- Allakos Appoints Neil Graham to its Board of Directors
- Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
More ▼
Key statistics
On Tuesday, Allakos Inc (ALLK:NSQ) closed at 1.39, 41.85% above the 52 week low of 0.9799 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.33 |
---|---|
High | 1.47 |
Low | 1.36 |
Bid | 1.39 |
Offer | 1.58 |
Previous close | 1.39 |
Average volume | 554.21k |
---|---|
Shares outstanding | 88.54m |
Free float | 86.26m |
P/E (TTM) | -- |
Market cap | 123.08m USD |
EPS (TTM) | -2.45 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼